Optimi Health Corp. operates as a pharmaceutical and nutraceutical drug manufacturing company in Canada. The company manufactures controlled substances including finished MDMA and psilocybin drug products, supplying them directly to authori…
Sign in to search companies, open filing PDFs, fetch uncached SEDAR+ documents, and use the
full company research view.
News 2026-06-10
Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial
News release - English.pdf
News 2026-06-08
Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development
News release - English.pdf
News 2026-06-02
Optimi Health Completes Commercial Psilocybin Production to Address Treatment-Resistant Depression in Australia
News release - English.pdf
Results 2026-06-01
Interim MD&A - English.pdf
Results 2026-06-01
Interim financial statements/report – English.pdf
News 2026-05-29
Optimi Health Welcomes Expanded Psychedelic-Assisted Therapy Access Under Updated Authorized Prescriber Framework in Australia
News release - English.pdf
Transactions 2026-05-26 Financing
Optimi Health Corp. Completes Uplisting to Nasdaq Capital Market and Closes US$15 Million Public Offering
Material change report - English.pdf
Transactions 2026-05-26 Financing
Report of exempt distribution (45-106F1).pdf
News 2026-05-26
Optimi Health Advances Highest-Purity Natural Psilocybin Extract to Date
News release - English.pdf
Transactions 2026-05-21 Financing
Optimi Health Announces Closing of Oversubscribed US$15 Million Public Offering
News release - English.pdf
Transactions 2026-05-20 Financing
Optimi Health Announces Pricing of Oversubscribed US$15 Million Public Offering and Nasdaq Uplisting
News release - English.pdf
Transactions 2026-04-23 Financing
Optimi Health Files LIFE Offering Document in Connection with Nasdaq Listing
News release - English.pdf
News 2026-04-20
Optimi Health Launches Ibogaine Initiative as U.S. Executive Order Signals Pathway for Psychedelic Drug Products
News release - English.pdf
News 2026-02-26
Optimi Health Reports Early Clinical Rollout of Natural Psilocybin Capsules for Treatment-Resistant Depression in Australia
News release - English.pdf
News 2026-02-19
Optimi Health Completes Psilocybin Export to Australia for Treatment Resistant Depression
News release - English.pdf
Results 2026-02-19 Financials
Interim MD&A - English.pdf
Results 2026-02-19 Financials
Interim financial statements/report – English.pdf
News 2026-02-17
Optimi Health Reports First MDMA-Assisted Treatments of 2026 are Underway Across an Expanded Network of Australian Clinics
News release - English.pdf
News 2026-02-09
Optimi Health Completes MDMA Export for PTSD Treatment Under Australia's Authorised Prescriber Scheme
News release - English.pdf
Results 2026-01-29 Financials
Annual MD&A - English.pdf
Results 2026-01-29 Financials
Audited annual financial statements – English.pdf
News 2026-01-26
Optimi Health Completes First 2026 Production of MDMA and Psilocybin Capsules
News release - English.pdf
News 2026-01-22
Early warning report.pdf
Ownership 2026-01-22
Early Warning Press Release in accordance with National Instrument 62-103
Press release - English.pdf
News 2025-11-26
Optimi Health to Supply MDMA to MAPS Israel's Clinical Trial for Trauma-Related PTSD
News release - English.pdf
News 2025-10-21
News release - English.pdf
News 2025-10-06
News release - English.pdf
News 2025-09-08
News release - English.pdf
News 2025-09-03
News release - English.pdf
Results 2025-08-30 Financials
Interim MD&A - English.pdf
Results 2025-08-30 Financials
Interim financial statements/report – English.pdf
News 2025-08-20
News release - English.pdf
News 2025-08-19
Other.pdf
News 2025-08-19
Other.pdf
News 2025-08-19
Other.pdf
News 2025-07-25
Early warning report.pdf
News 2025-07-25
Press release - English.pdf
News 2025-07-25
Report of exempt distribution (45-106F1).pdf
News 2025-07-25
Early warning report.pdf
News 2025-07-25
Press release - English.pdf
News 2025-07-25
Material change report - English.pdf
News 2025-07-18
News release - English.pdf
News 2025-06-23
Statement of executive compensation (form 51-102F6V) - English.pdf